Reading this on a mobile device? Try our optimized mobile version here:

February 14, 2013
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Intarcia tops 2012 list of biopharma equity deals
    Intarcia Therapeutics tops the list of the 10 biggest biopharma equity investment deals in 2012, according to reports from PricewaterhouseCoopers and the National Venture Capital Association. Alta Partners, New Leaf Venture Partners and Venrock were among the investors furthering Intarcia's development of a yearly, injection-free therapy for type 2 diabetes. Investments in Intrexon, Aragon Pharmaceuticals and Celladon also made the list. Genetic Engineering & Biotechnology News/Insight&Intelligence blog (2/12) LinkedInFacebookTwitterEmail this Story
Top 8 Obstacles in Pharma & Biologics Product Registration & Submission Management
For pharmaceutical and biologics companies, the path to a global product launch is full of obstacles that could result in delays to registrations, many of which can be avoided with the help of automation. This white paper identifies some of the most common problems in managing submissions for the purpose of product registration and how best to address them. Download the whitepaper.
  Health Care & Policy 
  • Amgen, UCB halt development of romosozumab for fracture healing
    Amgen and UCB said they would end their work on romosozumab, a humanized anti-sclerostin antibody, for fracture healing due to the results of a midstage trial and the high bar that fracture treatments must meet for approval. The firms will continue to develop the drug for the treatment of post-menopausal osteoporosis. PharmaTimes (U.K.) (2/13) LinkedInFacebookTwitterEmail this Story
  • Consortium unveils drug development project in EU
    The European Lead Factory, a global consortium that includes drugmakers, research groups and academics, introduced plans for a platform that will search half a million compound libraries to help support drug discovery in Europe. The project "will give European researchers unprecedented access to industry chemical collections and facilitate the translation of their findings into actual treatments for patients," said Michel Goldman, executive director of Europe's Innovative Medicines Initiative. (2/11) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Industry Deals 
  • Bristol licenses non-Rx drugs to Reckitt Benckiser for $482M
    Reckitt Benckiser is paying $482 million for rights to market some of Bristol-Myers Squibb's nonprescription medications in Latin America. The three-year deal includes the painkiller Tempra, the antacid Picot, and cough and cold drug Naldecon. After three years, Reckitt Benckiser will be given the option to acquire legal rights and intellectual property for the treatments. PharmaTimes (U.K.) (2/13) LinkedInFacebookTwitterEmail this Story
  • Qiagen will develop assays for Lilly's drugs
    Qiagen agreed to develop companion diagnostic tests for Eli Lilly & Co.'s experimental and approved drugs. The alliance expands Lilly's "capabilities to more quickly and cost-effectively bring innovative new medicines, alongside advanced diagnostics, to patients worldwide who are waiting," said Daniel Skovronsky, Lilly's vice president of tailored therapeutics. GenomeWeb Daily News (free registration) (2/13) LinkedInFacebookTwitterEmail this Story
  Food & Agriculture 
  • FDA extends comment period for biotech salmon
    The FDA extended until April 26 the public comment period for AquaBounty Technologies' biotech salmon, which grows twice as fast as traditional fish, after receiving nearly 30,000 responses so far. The agency will evaluate the comments and consider how to proceed, FDA spokesperson Morgan Liscinsky said. Preliminary assessments said no major environmental impact was posed by the fish. Canadian Press (2/13) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Obama wants $2B oil revenue invested in alt-fuels program
    President Barack Obama is urging Congress to steer $2 billion from oil and natural gas revenues into a new fund aimed at promoting cleaner vehicle technologies, according to a White House memo that adds details to a proposal in Tuesday's State of the Union address. "This $2 billion investment will support research into a range of cost-effective technologies -- like advanced vehicles that run on electricity, homegrown biofuels and domestically produced natural gas -- (and) will be funded by revenue generated from federal oil and gas development," the memo said. Reuters (2/13) LinkedInFacebookTwitterEmail this Story

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or 

  News from BIO 
  • Are you taking full advantage of your membership?
    BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Mistakes are part of the dues that one pays for a full life."
--Sophia Loren,
Italian actress

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information